Concepedia

Stéphane Cattan

SC

Statistics

Publications

26

Citations

6.4K

H-Index

22

Active since

2001

Affiliations

Centre Hospitalier Universitaire de Lille(Current)

Hôpital Claude Huriez

Kindai University

Chinese University of Hong Kong

Medizinische Hochschule Hannover

Stéphane Cattan is an author at Centre Hospitalier Universitaire de Lille specializing in medicine, oncology, and hepatocellular carcinoma pharmacotherapy.

Publications per year

2001–2024

26

Publications

26

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018 · 2.5K citations

, , +11

Long-Term Evolution of Disease Behavior of Crohn's Disease

Jacques Cosnes, Stéphane Cattan, Antoine Blain et al. · Inflammatory Bowel Diseases · 2002 · 1.4K citations · Full text

, , +17

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

Andrew X. Zhu, Masatoshi Kudo, Eric Assénat et al. · JAMA · 2014 · 569 citations · Full text

, , +17

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

, , +12

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

, , +16

1–5 of 26